Grundinformationen
- CAS
27470-51-5- Standard-SMILES
CCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O- InChIKey
ONWXNHPOAGOMTG-UHFFFAOYSA-N- Summenformel
- C24H26N2O6
- Durchschnittliche Molmasse
- 438,5 g/mol
- Monoisotopische Masse
- 438,17908655
Überblick
Suxibuzone is a pyrazolidine that is phenylbutazone which is substituted by a 3-carboxypropanoylmethyl group at the 4-position. Suxibuzone is a prodrug for phenylbutazone and is commonly used as an anti-inflammatory drug in horses. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antirheumatic drug, a peripheral nervous system drug and a prodrug. It is a hemisuccinate, a monocarboxylic acid and a member of pyrazolidines.
Namen und Bezeichner
- Bevorzugter Name
- Suxibuzone
- IUPAC
- 4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid
- Lokaler Name
- Suxibuzon
- Englischer Name
- 4-BUTYL-4-[HYDROXYMETHYL]-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE HYDROGEN SUCCINATE [ESTER]
- Summenformel
- C24H26N2O6
- Molmasse
- 438.47
Namen und Synonyme
suxibuzone27470-51-5SuxibuzonaSuxibuzonum4-((4-Butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy)-4-oxobutanoic acid4-Hydroxymethylbutazolidine hemisuccinateDTXSID60212964-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid86TDZ5WP2B4-Butyl-4-hydroxymethyl-1,2-diphenyl-3,5-pyrazolidinedione hydrogen succinateNSC-757866CHEBI:32173
Weitere Namen anzeigen
ae-17alfidesolurolAfloganlidinedione
DTXCID601296RefChem:8900701,2-Diphenyl-4-n-butyl-4-hydroxymethyl-3,5-dioxopyrazolidine Hemisuccinate4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedioneM02AA22248-477-6CalibeneFlogos
Datenbank-Bezeichner
- CAS
27470-51-5
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 3,6
- Polarare Oberfläche (TPSA)
- 104 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 6
- Frei drehbare Bindungen
- 11
- Schwere Atome
- 32
- Formalladung
- 0
- Komplexität
- 661
Experimentelle und physikochemische Eigenschaften
Human DrugsPharmaceuticals
Animal DrugsPharmaceuticals -> UK Veterinary Medicines Directorate List
Collision Cross Section
204.5 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID6021296]
199.3 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
202.05 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Physikochemische Eigenschaften
- Schmelzpunkt
- 126 · 126-127°
- Siedepunkt
- 550.33 °C · 550.33°C (rough estimate)
- Dichte
- 1.2847 · 1.2847 (rough estimate)
- Brechungsindex
- 1.63 · 1.6300 (estimate)
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- Practically insoluble in water, freely soluble in acetone, soluble in ethanol (96 per cent), practically insoluble in cyclohexane.
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 4 (100%)
Sicherheitsdaten
- wgk
- 3
- RTECS-Nr.
- WM9640000
- risk_code
- 20/21/22
- Toxizität
- LD50 orally in mice: 5.683 micromol/kg (Esteve, 1973)
- hazard_code
- Xn
- safety_code
- 36
- Speicherklasse
- 11 - Combustible Solids
- Hazard Classifications
- Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 Oral
Chemie und Industrie
Pharmakologische Informationen
ATC Code
M - Musculo-skeletal system
QM - Musculo-skeletal system
QM - Musculo-skeletal system
MeSH Pharmacological Classification
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Cellular LocationsMembrane
Verwendung und Herstellung
Use ClassificationPharmaceuticals
Anwendungen
Verwendenanalgesic, antipyretic, antiinflammatory
Anbieter55 Anbieter
艾吉析科技（上海）有限公司17717235263 · [email protected]
绍兴恒创合益生物科技有限公司15158234258 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]
陕西缔都新材料有限公司029-63373950 17392216152 · [email protected]
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…